Image

Intravital Microscopy in Human Solid Tumors

Intravital Microscopy in Human Solid Tumors

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated with solid tumors. The IVM observations may determine if an individual patient's tumor vessels would be amenable to receiving systemic therapy, based on the functionality of the vessels.

Description

PRIMARY OBJECTIVE:

I. To determine the feasibility of performing human intravital microscopy (HIVM) in patients with deep space solid tumors during standard course of surgical resection.

SECONDARY OBJECTIVES:

I. Compare the microscopic observation of the tumor-associated vessels with normal tissue (e.g. peritoneal surface or normal brain tissue) in each individual subject.

II. Correlate the microscopic observations of the tumor-associated vessels with pathologic grade of tumor.

III. To correlate the microscopic observation of the microvasculature with tumor-specific and overall survival.

OUTLINE

Patients receive fluorescein intravenously (IV) and undergo HIVM over 1-2 minutes per field.

After completion of study, patients are followed up at 2-3 weeks after surgery.

Eligibility

Inclusion Criteria:

  • Age ≥ 18 years of age
  • Eastern Cooperative Oncology Group (ECOG)Performance Status of ≤ 2
  • Measurable tumor by direct visualization requiring surgical resection in the operating room (OR)
  • Tumor types of origin include gastric, pancreatic, hepatobiliary, colorectal, sarcoma, brain, or breast cancer that may involve the axillary lymph nodes cancers. Tumors may be primary or metastatic
  • Subject must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent
  • Subject must have a skin prick test pre-operatively (at the time of the preoperative visit and after signed informed consent for entry into this clinical trial is given) to determine any sensitivity to fluorescein

Exclusion Criteria:

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
  • Renal dysfunction as defined as a glomerular filtration rate (GFR) < 45
  • Liver dysfunction as defined by Child-Pugh score > 5, or liver function test (LFT)'s 1.5 x above normal range
  • Any known allergy or prior reaction to fluorescein or a positive skin prick test to fluorescein
  • Pregnant or nursing female subjects, determined preoperatively with a urine pregnancy test
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the investigators' opinion deems the patient unsuitable (e.g., abnormal electrocardiography [EKG], including T wave inversion, elevated T waves, prolonged QRS interval, or conduction blocks) or that requires further work-up (including cardiac echo or stress test)
  • Any condition that excludes surgical resection as the standard of care for the patient

Study details
    Solid Tumor
    Adult
    Clinical Stage IV Gastric Cancer AJCC v8
    Malignant Solid Neoplasm
    Metastatic Colorectal Carcinoma
    Metastatic Gastric Carcinoma
    Metastatic Primary Malignant Brain Neoplasm
    Metastatic Sarcoma
    Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8
    Resectable Colorectal Carcinoma
    Resectable Liver and Intrahepatic Bile Duct Carcinoma
    Resectable Pancreatic Carcinoma
    Resectable Sarcoma
    Stage IV Colorectal Cancer AJCC v8
    Anatomic Stage IV Breast Cancer AJCC v8
    Malignant Brain Neoplasm
    Metastatic Breast Carcinoma
    Metastatic Liver Carcinoma
    Metastatic Pancreatic Carcinoma
    Resectable Brain Neoplasm
    Resectable Breast Carcinoma
    Resectable Gastric Carcinoma
    Stage IV Hepatocellular Carcinoma AJCC v8
    Stage IV Pancreatic Cancer AJCC v8

NCT03823144

Mayo Clinic

16 July 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.